Literature DB >> 25098631

Combined liver and lung transplantation with extended normothermic lung preservation in a patient with end-stage emphysema complicated by drug-induced acute liver failure.

L J Ceulemans1, D Monbaliu, C Verslype, S van der Merwe, W Laleman, R Vos, A Neyrinck, H Van Veer, P De Leyn, F Nevens, J Pirenne, G Verleden, D Van Raemdonck.   

Abstract

Isolated lung transplantation (LuTx) and liver transplantation are established treatments for irreversible lung and liver failure. Combined liver and lung transplantation (cLiLuTx) is a less common, but approved therapy of combined organ failure, mostly applied in patients suffering from progressive cystic fibrosis and advanced liver disease. We report a patient who was listed for LuTx due to end-stage chronic obstructive pulmonary disease and who developed drug-induced acute hepatic failure. The only therapeutic option was hyper-urgent cLiLuTx. To correct the poor coagulation in order to reduce the per-operative risk of bleeding, the liver was transplanted first. In anticipation of the longer lung preservation time, cold flushed lungs were preserved on a portable lung perfusion device for ex vivo normothermic perfusion for 11 h 15 min, transplanted sequentially off-pump, and reperfused after a total ex vivo time of 13 h 32 min and 16 h for the first and second lung, respectively. Ten months later, the patient is doing well and no rejection occurred. Normothermic ex vivo lung perfusion may help to prolong preservation time, facilitating long-distance transport and combined organ transplantation. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Clinical research; drug toxicity; dysfunction; hepatology; liver (native) function; liver transplantation; lung (allograft) function; lung transplantation; organ perfusion and preservation; organ transplantation in general; practice; pulmonology

Mesh:

Year:  2014        PMID: 25098631     DOI: 10.1111/ajt.12856

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  6 in total

1.  Prolonged EVLP Using OCS Lung: Cellular and Acellular Perfusates.

Authors:  Gabriel Loor; Brian T Howard; John R Spratt; Lars M Mattison; Angela Panoskaltsis-Mortari; Roland Z Brown; Tinen L Iles; Carolyn M Meyer; Haylie R Helms; Andrew Price; Paul A Iaizzo
Journal:  Transplantation       Date:  2017-10       Impact factor: 4.939

2.  A Propensity-matched Survival Analysis: Do Simultaneous Liver-lung Transplant Recipients Need a Liver?

Authors:  Kyle Freischlag; Brian Ezekian; Paul M Schroder; Michael S Mulvihill; Morgan L Cox; Matthew G Hartwig; Stuart Knechtle
Journal:  Transplantation       Date:  2019-08       Impact factor: 4.939

Review 3.  Recipient selection process and listing for lung transplantation.

Authors:  Geert M Verleden; Lieven Dupont; Jonas Yserbyt; Veronique Schaevers; Dirk Van Raemdonck; Arne Neyrinck; Robin Vos
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

4.  Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes.

Authors:  Kyle William Freischlag; Julia Messina; Brian Ezekian; Michael S Mulvihill; Andrew Barbas; Carl Berg; Debra Sudan; John Reynolds; Matthew Hartwig; Stuart Knechtle
Journal:  Transplant Direct       Date:  2018-04-26

Review 5.  Ex vivo lung perfusion.

Authors:  Tatsuaki Watanabe; Marcelo Cypel; Shaf Keshavjee
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

Review 6.  Normothermic Ex-vivo Liver Perfusion and the Clinical Implications for Liver Transplantation.

Authors:  Clifford Akateh; Eliza W Beal; Bryan A Whitson; Sylvester M Black
Journal:  J Clin Transl Hepatol       Date:  2018-05-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.